I’ve spent months buried in research that keeps pointing to the same uncomfortable conclusion: we’ve been treating mast cell activation syndrome at the wrong level.
Not the wrong disease. The wrong level of the disease.
The standard approach targets mast cells directly — suppress them, stabilize them, block their receptors. And for acute symptom relief, that approach has real value. But it doesn’t explain why the mast cells became hyperactive in the first place. It doesn’t address what changed upstream. And it doesn’t offer a path back to a state where your immune system regulates itself without pharmaceutical scaffolding.
What I’ve been tracing is a different chain entirely — one that starts in your gut, runs through your mitochondria, and ends at the molecular switches that determine whether your mast cells behave or not.
When you follow that chain all the way back, the picture changes completely.
First: What Is a Mast Cell, and What Is It Actually Doing?
Before we get into why mast cells go wrong, it helps to understand what they’re supposed to do.
Mast cells are immune cells that live in your tissues — not just in your gut, but throughout your body: your skin, lungs, nasal passages, brain lining, and connective tissue. They’re essentially first responders. When they detect something threatening — a pathogen, a toxin, a physical injury — they release a burst of chemical mediators stored in internal granules. Histamine is the most well-known, but they also release tryptase, prostaglandins, leukotrienes, and dozens of cytokines.
That release — called degranulation — is what causes the symptoms associated with mast cell activation: flushing, hives, swelling, GI cramping, brain fog, heart palpitations, breathing difficulty. In the right context, degranulation is protective. It’s your immune system doing exactly what it should.
The problem in MCAS isn’t that mast cells degranulate. It’s that they degranulate at the wrong threshold — firing at stimuli that shouldn’t trigger them, or firing continuously without a clear trigger at all.
The question is: what sets that threshold? And what lowers it pathologically?
The answer, it turns out, is not primarily structural. It’s not that the mast cells are malformed. It’s that the molecular system that determines how sensitive mast cells are has been dysregulated at the epigenetic level. And that epigenetic dysregulation has a metabolic cause.
The Concept You Need to Understand: Epigenetics
“Epigenetics” is one of those words that gets used a lot without being properly explained. Let me give you the version that actually makes sense of what’s happening in MCAS.
Your DNA contains roughly 20,000 genes. Every cell in your body carries the full set — but not every cell uses the same genes. A liver cell and a mast cell have identical DNA, but they behave completely differently because different genes are active in each one.
What controls which genes are active? Epigenetic tags — chemical modifications attached to DNA and to the proteins (called histones) that DNA wraps around.
Think of it this way: your DNA is like a massive library of books. Epigenetic tags are the system that decides which books are on the open shelf and which are locked in the back room. A tag called methylation on a gene’s promoter region is essentially a lock — it tells the cell’s reading machinery “don’t open this.” A different configuration of tags does the opposite — it opens the book and makes the gene readable.
Here’s the critical part that most explanations skip: these tags are not permanent and they are not passive. They are actively maintained by enzymes that add and remove them on an ongoing basis. Those enzymes require specific molecules to function — primarily NAD⁺ (nicotinamide adenine dinucleotide) and α-ketoglutarate (α-KG).
These aren’t exotic compounds. NAD⁺ is central to how your mitochondria generate energy. α-KG is an intermediate in the TCA cycle — the core metabolic loop that every cell uses to convert nutrients into usable fuel. Both are produced continuously in healthy cells.
But when cellular metabolism is disrupted — when the fuel supply chains that generate NAD⁺ and α-KG are broken — the enzymes that maintain epigenetic tags run out of what they need to do their job. Tags that were keeping inflammatory genes locked away start to slip. Tags that were keeping regulatory “calm down” signals active start to erode.
The result is a slow, progressive loss of epigenetic control over immune gene expression. And mast cells — which sit at the intersection of immune surveillance and inflammatory response — are among the most sensitive readouts of that loss.
Where the Fuel Comes From — and Where It Breaks Down
To understand why NAD⁺ and α-KG fall in the first place, you need to understand a supply chain that most people have never been told about.
It starts in your gut.
Your colon is lined with specialized cells called colonocytes. These cells have a unique metabolic feature: unlike most cells in the body, which run primarily on glucose, colonocytes prefer to burn butyrate — a short-chain fatty acid produced when gut bacteria ferment dietary fiber.
Butyrate enters colonocytes through a transporter called SLC5A8, gets converted to acetyl-CoA inside the mitochondria, and feeds directly into the TCA cycle. That TCA cycle activity generates α-KG as an intermediate and drives the electron transport chain, which regenerates NAD⁺. In other words: healthy gut bacteria → butyrate → colonocyte mitochondrial activity → NAD⁺ and α-KG production.
This isn’t just local. Colonocyte metabolism appears to have systemic effects on NAD⁺ availability — particularly through the production of NAD⁺ precursors and through the maintenance of gut barrier integrity, which determines how much metabolic stress the rest of the body is under.
Now introduce dysbiosis — a disruption of the gut microbial community that reduces butyrate-producing species. Suddenly colonocytes are fuel-starved. Their mitochondria underperform. TCA cycle flux drops. NAD⁺ regeneration slows. α-KG production falls.
Simultaneously, a damaged gut barrier allows bacterial products — particularly lipopolysaccharide (LPS), a component of gram-negative bacterial cell walls — to leak into systemic circulation. LPS activates the enzyme CD38, which aggressively consumes NAD⁺ as part of the inflammatory signaling cascade. This creates a double hit: less NAD⁺ being produced, more NAD⁺ being destroyed.
The result is systemic NAD⁺ and α-KG depletion — and the epigenetic machinery that depends on both starts to fail.
The Three Locks That Are Failing — And Why
Here are the three specific epigenetic mechanisms I’m tracking in MCAS, and exactly how each one breaks down when metabolic fuel runs out.
Lock 1: DNMT3A — The Gene Silencer
DNMT3A is a DNA methyltransferase — an enzyme whose job is to place methyl tags on the promoter regions of inflammatory genes. When those tags are in place, the gene is silenced. The cell’s gene-reading machinery cannot access it. Inflammatory output stays low.
DNMT3A’s activity is critically dependent on a molecule called SAM (S-adenosylmethionine) as the methyl group donor. But its functional state — whether it’s in an active conformation or not — is regulated by SIRT1, a deacetylase enzyme that runs on NAD⁺.
The chain: NAD⁺ falls → SIRT1 activity drops → DNMT3A loses its active configuration → methylation of inflammatory gene promoters slows → silencing marks erode over time.
This erosion isn’t fast. It happens over weeks and months, which is why MCAS often develops gradually. Patients frequently describe a slow loss of tolerance — foods they handled fine before become triggers, symptoms that were occasional become constant — without being able to identify a single event that caused it. That gradual course is consistent with slow epigenetic drift driven by progressive NAD⁺ depletion.
The inflammatory genes most affected include TNF-α, IL-6, and Spp1 — which encodes a protein called osteopontin that we’ll return to shortly.
Lock 2: TET2 — The Tolerance Writer
TET2 works in a complementary direction. Rather than silencing inflammatory genes, TET2 activates tolerance and regulatory genes — the signals that tell immune cells, including mast cells, that the environment is safe and that mounting an inflammatory response is not appropriate.
TET2 does this by chemically modifying methylated bases on DNA (converting 5-methylcytosine to 5-hydroxymethylcytosine), which is the first step in removing silencing marks from regulatory gene regions. This is how your immune system continuously refreshes its “calm down” signals.
The critical detail: TET2 is an α-ketoglutarate-dependent dioxygenase. It uses α-KG as an obligate cofactor. Without α-KG, the chemical reaction that TET2 catalyzes simply does not occur.
So when α-KG falls — driven by colonocyte mitochondrial dysfunction and reduced TCA cycle flux — TET2 stalls. The regulatory genes that should be continuously kept active go quiet. The “all clear” signals that mast cells require to stand down stop being generated.
Mast cells never receive the signal to relax. They remain in a primed, hair-trigger state — not because they’re defective, but because the system that would tell them to calm down has gone silent.
This is why mast cell symptoms can persist even when there’s no apparent ongoing trigger. The problem isn’t the trigger. It’s the absence of the counter-signal.
Lock 3: H3K9 Methylation at the Spp1 Locus — The Threshold Controller
This one is more specific but critically important for understanding why MCAS patients experience escalating sensitivity over time.
The Spp1 gene encodes osteopontin — a cytokine that directly lowers the activation threshold of mast cells. Higher osteopontin means mast cells degranulate more easily, at lower stimulus intensity, with less specificity about what triggers them.
In a healthy state, the Spp1 gene is kept in a locked, condensed state by a histone modification called H3K9me3 — trimethylation of histone H3 at lysine 9. This mark is placed and maintained by histone methyltransferases that also depend on α-KG-derived metabolites.
When α-KG is chronically depleted, H3K9me3 marks at the Spp1 locus erode. The gene opens. Osteopontin is produced. And now mast cells aren’t just missing their regulatory brakes — they’re also being actively driven toward lower activation thresholds by a cytokine circulating in their environment.
This is the mechanism behind the clinical pattern MCAS patients describe so consistently: things keep getting worse, not better. More triggers. Lower thresholds. Reactions to things that never bothered them before. The progressive nature isn’t random and it isn’t psychological. It’s the epigenetic landscape being systematically remodeled toward hyperreactivity.
There’s a further implication that deserves serious attention: chronic α-KG depletion at these critical loci may eventually produce somatic mutations. Specifically, loss-of-function mutations in TET2 itself, gain-of-function mutations in KIT (KIT D816V), and mutations in DNMT3A (R882H) — the exact mutations found in systemic mastocytosis and clonal mast cell disorders. This suggests a possible progression pathway: metabolic failure drives epigenetic dysregulation, epigenetic dysregulation creates genomic instability at immune regulatory loci, and over time that instability produces the mutations that define clonal disease. This is not yet proven in the way I’m framing it, but it’s mechanistically consistent and warrants serious investigation.
Why Current Treatments Work — and Where They Stop
I want to be fair about conventional MCAS treatment, because it does work — at a specific level.
Antihistamines (cetirizine, loratadine, famotidine) block histamine receptors after histamine has been released. They reduce the downstream effects of degranulation without stopping the degranulation itself. For acute symptom control, this is genuinely valuable.
Mast cell stabilizers (cromolyn sodium, ketotifen) work slightly upstream — they reduce the likelihood of degranulation by stabilizing the mast cell membrane. Ketotifen also has antihistamine properties. These are closer to the source of the problem.
Montelukast blocks leukotriene receptors — another mediator pathway downstream of degranulation. Useful for respiratory and inflammatory symptoms specifically.
For patients with confirmed clonal disease — KIT D816V mutation, elevated serum tryptase above 50 ng/mL, bone marrow involvement — avapritinib (a KIT inhibitor) has shown remarkable efficacy. This is appropriate pharmacotherapy for a specific, confirmed disease state.
The limitation of all of these approaches, including avapritinib, is that none of them address the upstream metabolic and epigenetic failure that drove mast cell dysregulation in the first place. Even avapritinib, which targets a specific mutation, doesn’t explain how that mutation arose or whether the metabolic conditions that created it are still active.
Treating symptoms without addressing root cause is not wrong. Sometimes it’s necessary and life-improving. But it’s also incomplete — and for the large majority of MCAS patients who don’t have confirmed clonal disease, it leaves the actual cause entirely untouched.
What Metabolic Restoration Actually Targets
When I talk about metabolic restoration for MCAS, I’m describing an intervention strategy that works at the level of cause rather than symptom. Here’s what it targets and why:
NAD⁺ repletion addresses the SIRT1-DNMT3A axis directly. NAD⁺ precursors — primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — can raise cellular NAD⁺ levels when administered orally. Restoring NAD⁺ allows SIRT1 to resume its function, which restores DNMT3A’s active conformation, which allows methylation of inflammatory gene promoters to be re-established. This is not a supplement claim — it’s a mechanistic prediction based on the known biochemistry of the SIRT1-DNMT3A interaction.
Microbiome rehabilitation addresses butyrate production — the source of colonocyte fuel. This means not just adding probiotic bacteria, but specifically rebuilding communities of butyrate-producing species (Faecalibacterium prausnitzii, Roseburia intestinalis, Butyricicoccus pullicaecalis) and providing the fermentable substrates they require. Without the right fiber substrates, even the right bacteria can’t produce adequate butyrate.
Barrier repair reduces LPS translocation — which reduces the CD38-driven NAD⁺ consumption that’s accelerating depletion. Specific interventions that support tight junction integrity (zinc carnosine, colostrum, certain prebiotics) reduce the chronic inflammatory drain on NAD⁺ reserves.
Mitochondrial support in colonocytes specifically — ensuring that the cells lining the colon have what they need to run the TCA cycle efficiently, generate α-KG, and sustain the metabolic output that the rest of the system depends on.
α-KG precursor support — directly providing substrates that can raise α-KG availability (including certain amino acids and TCA cycle intermediates) to support TET2 function while the gut-mitochondria axis is being rebuilt from the bottom up.
The sequencing of these interventions matters as much as the interventions themselves. The clinical framework I’m building determines which comes first — and for which clinical phenotype.
The Three Clinical Patterns I’m Mapping
Not all MCAS presentations are identical, and I’ve been finding that the underlying metabolic failure pattern varies across patients in clinically meaningful ways.
Pattern A — Gut-Dominant MCAS: The primary driver is dysbiosis with significant butyrate deficiency. These patients typically have prominent GI symptoms alongside mast cell features, often have a history of antibiotic exposure, and show signs of barrier dysfunction (food sensitivities, elevated zonulin, intestinal permeability markers). The metabolic failure is most concentrated in the colonocyte-mitochondria axis.
Pattern B — Systemic NAD⁺ Collapse: The gut component may be present but less dominant. These patients show broader systemic features — fatigue, widespread inflammation, immune dysregulation across multiple systems, often overlapping with chronic fatigue or fibromyalgia presentations. The metabolic failure is more diffuse, with NAD⁺ depletion being the central driver rather than butyrate deficiency specifically.
Pattern C — CNS and Autonomic Dominant MCAS: These patients have prominent neurological and autonomic features — brain fog, cognitive dysfunction, autonomic instability, POTS overlap, and significant neuroinflammatory symptoms. The mast cell dysregulation in this pattern extends into the CNS, involving brain-resident mast cells and potentially blood-brain barrier breakdown. This is the pattern most commonly seen in the hEDS/POTS/MCAS cluster, and it requires the most complex intervention sequencing.
Each pattern requires a different intervention emphasis and different outcome expectations. This mapping is still in progress, but it’s already changing how I approach initial client assessment.
What I’m Doing Right Now
I’m currently working across five tracks simultaneously:
Clinical testing: Running metabolic restoration protocols with MCAS clients over 8–16 week windows, tracking serum tryptase, hs-CRP, antihistamine use, food tolerance, and symptom load at regular intervals.
Mechanistic validation: Determining whether NAD⁺ repletion, microbiome rehabilitation, and barrier repair actually produce measurable shifts in mast cell reactivity — and in what sequence those shifts appear.
Phenotype mapping: Building enough client data to clearly distinguish the three patterns above, identify which interventions move the needle for which phenotype, and define realistic outcome timelines for each.
Framework formalization: Translating the mechanistic chain — from dysbiosis to colonocyte failure to NAD⁺/α-KG depletion to epigenetic dysregulation to mast cell hyperactivation — into a complete clinical decision model.
Publishing: A full mechanistic research article is coming in the next few weeks, with the complete biological chain, the clinical framework, and early case data.
The Hope I Want You to Have — and the Realism That Comes With It
If you’ve been told “you have MCAS and you’ll always need antihistamines” — or “you probably have a mutation and need a specialized drug” — or simply “learn to manage it” — I want to offer a framing you likely haven’t been given:
What if your mast cells aren’t broken? What if the system that regulates them has been starved of the fuel it needs to function?
Because when I look at the research — Leoni’s work on DNMT3A in mast cell regulation, Molderings’ research on familial mast cell disease, the documented connections between TET2 loss-of-function and mast cell clonal expansion, and the growing literature on metabolic-epigenetic coupling in immune conditions — the pattern is consistent. Mast cell dysregulation, in most cases, is not the origin of the problem. It is the downstream consequence of a metabolic failure that began somewhere else.
And downstream consequences can be addressed by fixing what’s upstream.
This is not a simple fix. Genuine metabolic restoration takes time — typically 8–16 weeks of consistent, sequenced intervention. It requires identifying which pattern you fit and which interventions are actually relevant to your biology. And if you have confirmed clonal mast cell disease — elevated serum tryptase above 50 ng/mL, bone marrow findings, confirmed KIT D816V — you likely need pharmacotherapy alongside this work, not instead of it.
But for the majority of MCAS patients — those without confirmed clonal disease, those whose tryptase is modestly elevated or normal, those whose symptoms are driven by functional dysregulation rather than genetic mutation — the metabolic-epigenetic framework offers a real path to restoration, not just management.
Your mast cells were not always this reactive. Something changed. Understanding what changed is the first step toward reversing it.
What’s Coming
A full mechanistic research article — the complete chain from dysbiosis to epigenetic mast cell dysregulation, with the clinical protocol built from it — is coming in the next few weeks.
Case studies will follow: before-and-after data from clients going through metabolic restoration, including tryptase levels, antihistamine use, symptom severity, and food tolerance progression.
And all of this is being integrated into the Host Capacity Model — a unified framework for understanding MCAS, dysautonomia, neuroinflammation, and chronic immune dysregulation not as separate diagnoses requiring separate treatments, but as interconnected expressions of a single upstream failure: depleted metabolic fuel and the epigenetic dysregulation that follows it.
Because managing symptoms was never the goal.
The goal is restoring enough metabolic capacity that your body can regulate its own immune system again — the way it was always designed to.
Mohammed Attallah is an independent systems biology researcher and practitioner. He publishes mechanistic content on Substack and Medium, and works directly with clients through his consulting practice. Contact: research@biomelogic.net